TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
about
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignanciesTAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.Inhibiting 4EBP1 in glioblastoma.m-TOR inhibitors and their potential role in haematological malignancies.Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.Identification of four potential predicting miRNA biomarkers for multiple myeloma from published datasets.The PI3K Pathway in Human Disease.CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro.PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma.Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.Biological Aspects of mTOR in Leukemia
P2860
Q28817964-1EA33490-2E4F-4B93-BC03-0EEA1932748DQ33442621-D610ABC1-4038-4B25-8F5A-192A681502ADQ37687122-8B5286CA-0F47-4363-A786-A8C64360893EQ38659417-57C47D78-C849-4DA5-B11B-FF518F3E979FQ39113506-95AADC89-262A-4FA4-AB73-0B0BC10EF8B0Q39326047-F463A697-D85E-4CB3-B712-7313F3370CBAQ42324421-54F9DBB0-76F5-42EE-A46E-AF44318A88CAQ46546002-D3357923-82AF-43AF-8652-FF9C39E0E005Q47101683-F3255402-138C-47FE-866E-0AECB03EFA7BQ48263465-ABACDC62-248F-4853-9ED1-E1AB59D78F4FQ49787386-1D3D5319-7849-4F89-A064-AF6DDB259274Q52092512-5D99CB40-6E96-4B2A-9E7A-D726AB11CBD2Q53704366-6B20D051-C437-4EA6-99EF-5D77B52C2C5BQ54110134-B70BAFAF-4EA5-47FB-8714-C7D2489CB180Q55010628-F52E216E-7096-439A-A8ED-C58B7DEA6C2AQ55111944-CCE88B77-FCF8-4266-AB33-8385C502628EQ58780065-587F0B0D-BF83-4E14-94C5-5CAF1A1C9A7B
P2860
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@ast
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@en
type
label
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@ast
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@en
prefLabel
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@ast
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@en
P2093
P2860
P356
P1476
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@en
P2093
Chirag G Patel
David S Siegel
Fabian Zohren
Irene M Ghobrial
Jeffrey L Wolf
Jesus G Berdeja
Rachel Neuwirth
P2860
P304
P356
10.1002/AJH.24300
P577
2016-01-22T00:00:00Z